logo
Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137
rus
русский
eng
english

Site search



Correspondence address
310 Mira Street, Stavropol, Russia, 355017

Tel
+7 8652 352524; +7 8652 353229.

Fax
+7 8652 352524.

E-mail
medvestnik@stgmu.ru

Role of galectin -3 in diagnostics and treatment control in patients with heart failure

[Clinical Pharmacology] [Pharmacology]
Vladimir Kukes; Karine Gyamdzhyan; Anna Zhestovskaia; Yury Olefir; Valeriy Marinin; Alexey Prokofiev;

The aim of the study was to assess clinical value of galectin-3 levels evaluation in patients with heart failure. The study results demonstrated decrease of plasma galectin-3 levels after pharmacotherapy. The decrease of galectin-3 levels was accompanied by clinical improvement in patients with heart failure. Thus, galectin-3 can be used as an additional biomarker for HF diagnostics and pharmacotherapy monitoring in patients with heart failure.

Download

References:
1. Kim H., Lee J., Hyun J. W., Park J. W., Joo H., Shin T. Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell. Biol. Int. 2007;31(7):655-662.
2. Tang W. H. W., Shrestha K., Shao Z., Borowski A. G. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am. J. Cardiol. 2011;108(3):385-390. https://doi.org/10.1016/j.amjcard.2011.03.056
3. Ueland T., Aukrust P., Broch K., Aakhus S. Galectin-3 in heart failure: High levels are associated with allcause mortality. Int. J. Cardiol. 2011;150(3):361-364. https://doi.org/10.1016/j.ijcard.2011.05.081
4. Mareev V. Yu., Fomin I. V., Ageev F. T., Arutyunov G. P., Begrambekova Yu. L., Belenkov Yu. N. Klinicheskie rekomendacii. Khronicheskaya serdechnaya nedostatochnost. Serdechnaya nedostatochnost. – Heart Failure Journal. (XSN). 2017;18(1):3-40. (In Russ). https://doi.org/10.18087/rhfj.2017.1.2346
5. Anand I. S., Rector T. S., Kuskowski M., Adourian A., Muntendam P., Cohn J. N. Baseline and serial measurements of galectin-3 in patients with heart failure: Relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur. J. Heart Fail. 2013;15(5):511-518. https://doi.org/10.1093/eurjhf/hfs205
6. Motiwala S. R., Szymonifka J., Belcher A., Weiner R. B. Serial measurement of galectin-3 in patients with chronic heart failure: Results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur. J. Heart Fail. 2013;15(10):1157-1163. https://doi.org/10.1093/eurjhf/hft075
7. van Kimmenade R. R., Januzzi J. L., Ellinor P. T., Sharma U. C. Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure. J. Am. Coll. Cardiol. 2006;48(6):1217-1224. https://doi.org/10.1016/j.jacc.2006.03.061
8. Januzzi J. L., Camargo C. A., Anwaruddin S., Baggish A. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am. J. Cardiol. 2005;95(8):948-954. https://doi.org/10.1016/j.amjcard.2004.12.032
9. Deveci O. S., İelik A. İ., İkikardeş M. F., Cagliyan C. E. A Novel BioTarget in Treatment of Heart Failure: Changes in Serum Galectin-3 Levels after Spironolactone Therapy. J. Hypertens. Open. Access. 2015;04(01):1-4. https://doi.org/10.4172/2167-1095.1000195
10. Richards A. M., Doughty R., Nicholls M. G., MacMahon S. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. J. Am. Coll. Cardiol. 2001;37(7):1781-1787. https://doi.org/10.1016/S0735-1097(01)01269-4

Keywords: galectin-3, NT-proBNP, biomarkers, chronic heart failure


Founders:
Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy